Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM
Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) shareholders approved the appointment of Deloitte Accountants B.V. as the new independent auditor for the financial year ending December 31, 2024, at an Extraordinary General Meeting (EGM) held on October 18, 2024. This decision follows the Board of Directors' proposal to rotate auditors in line with good governance practices. The previous auditor had been in place since 2016.
The EGM saw a representation of 8,367,544 ordinary shares, constituting 47.70% of Cosmo's total outstanding ordinary shares as of the record date. This change in auditors reflects Cosmo's commitment to maintaining strong corporate governance standards.
Gli azionisti di Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) hanno approvato la nomina di Deloitte Accountants B.V. come nuovo revisore indipendente per l'esercizio finanziario che si concluderà il 31 dicembre 2024, durante un'Assemblea Generale Straordinaria (EGM) tenutasi il 18 ottobre 2024. Questa decisione segue la proposta del Consiglio di Amministrazione di ruotare i revisori in linea con le buone pratiche di governance. Il revisore precedente era in carica dal 2016.
Durante l'EGM, c'è stata una rappresentanza di 8.367.544 azioni ordinarie, che costituiscono il 47,70% del totale delle azioni ordinarie in circolazione di Cosmo alla data di registrazione. Questo cambiamento di revisori riflette l'impegno di Cosmo a mantenere standard elevati di governance societaria.
Los accionistas de Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) aprobaron el nombramiento de Deloitte Accountants B.V. como nuevo auditor independiente para el ejercicio financiero que finaliza el 31 de diciembre de 2024, en una Junta General Extraordinaria (EGM) celebrada el 18 de octubre de 2024. Esta decisión sigue la propuesta de la Junta Directiva de rotar auditores en línea con las buenas prácticas de gobernanza. El auditor anterior había estado en su puesto desde 2016.
La EGM contó con una representación de 8.367.544 acciones ordinarias, que constituyen el 47,70% del total de acciones ordinarias en circulación de Cosmo a la fecha de registro. Este cambio de auditores refleja el compromiso de Cosmo de mantener altos estándares de gobernanza corporativa.
코스모 제약 N.V. (SIX: COPN, FSE: C43)의 주주들은 2024년 12월 31일 종료되는 회계연도의 새로운 독립 감사인으로 딜로이트 회계법인을 임명하는 것을 승인했습니다. 이 결정은 좋은 거버넌스 관행에 따라 감사인을 교체하자는 이사회 제안에 따른 것입니다. 이전 감사인은 2016년부터 재직해왔습니다.
EGM에서는 8,367,544주 보통주의 대표성이 나타났으며, 이는 코스모의 총 발행 보통주의 47.70%를 차지합니다. 감사인 변경은 코스모의 강력한 기업 거버넌스 기준 유지를 향한 약속을 반영합니다.
Les actionnaires de Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) ont approuvé la nomination de Deloitte Accountants B.V. en tant que nouveau réviseur indépendant pour l'exercice financier se terminant le 31 décembre 2024, lors d'une Assemblée Générale Extraordinaire (AGE) tenue le 18 octobre 2024. Cette décision fait suite à la proposition du Conseil d'administration de changer de réviseur conformément aux bonnes pratiques de gouvernance. Le réviseur précédent était en poste depuis 2016.
Lors de l'AGE, il y a eu une représentation de 8.367.544 actions ordinaires, ce qui constitue 47,70% du total des actions ordinaires en circulation de Cosmo à la date d'enregistrement. Ce changement de réviseur reflète l'engagement de Cosmo à maintenir des normes de gouvernance d'entreprise élevées.
Die Aktionäre von Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) haben die Ernennung von Deloitte Accountants B.V. als neuen unabhängigen Prüfer für das am 31. Dezember 2024 endende Finanzjahr während einer außergewöhnlichen Hauptversammlung (EGM) am 18. Oktober 2024 genehmigt. Diese Entscheidung folgt dem Vorschlag des Vorstands, die Prüfer im Einklang mit guten Governance-Praktiken zu rotieren. Der vorherige Prüfer war seit 2016 im Amt.
Die EGM verzeichnete eine Vertretung von 8.367.544 Stammaktien, die 47,70 % der insgesamt ausgegebenen Stammaktien von Cosmo ausmachten zum Zeitpunkt der Hauptversammlung. Dieser Wechsel des Prüfers spiegelt das Engagement von Cosmo wider, hohe Standards der Unternehmensführung aufrechtzuerhalten.
- Appointment of a new independent auditor (Deloitte Accountants B.V.) for improved financial oversight
- Demonstration of good corporate governance through auditor rotation
- None.
Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024.
Cosmo’s previous auditor was appointed as independent auditor in 2016. Having given consideration to good governance practices in relation to rotation of auditors, the Board of Directors proposed to select a new independent auditor.
A total of 8,367,544 ordinary shares of the share capital of Cosmo were represented at this Extraordinary General Meeting (EGM) of shareholders, constituting
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Calendar of Events
UBS Global Healthcare Conference, California November 11-14, 2024
Jefferies London Healthcare Conference, London November 19-21, 2024
For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
PDF - English
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227054
FAQ
What was the main decision made at Cosmo Pharmaceuticals' EGM on October 18, 2024?
Why did Cosmo Pharmaceuticals (CMOPF) change its independent auditor?
What percentage of Cosmo Pharmaceuticals' (CMOPF) shares were represented at the October 18, 2024 EGM?
